Indiana Trust & Investment Management CO Has $341,000 Stock Position in CVS Health Co. (NYSE:CVS)

Indiana Trust & Investment Management CO cut its stake in shares of CVS Health Co. (NYSE:CVS) by 38.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,280 shares of the pharmacy operator’s stock after selling 2,680 shares during the quarter. Indiana Trust & Investment Management CO’s holdings in CVS Health were worth $341,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in CVS Health by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 117,696,285 shares of the pharmacy operator’s stock valued at $9,293,299,000 after acquiring an additional 533,659 shares during the period. Capital World Investors boosted its stake in CVS Health by 0.3% during the 4th quarter. Capital World Investors now owns 40,544,702 shares of the pharmacy operator’s stock valued at $3,201,410,000 after purchasing an additional 119,631 shares during the last quarter. Capital International Investors lifted its holdings in shares of CVS Health by 47.4% in the fourth quarter. Capital International Investors now owns 33,691,698 shares of the pharmacy operator’s stock valued at $2,660,298,000 after purchasing an additional 10,837,801 shares in the last quarter. Royal Bank of Canada grew its holdings in CVS Health by 2.2% during the third quarter. Royal Bank of Canada now owns 14,136,920 shares of the pharmacy operator’s stock worth $987,041,000 after buying an additional 303,512 shares in the last quarter. Finally, Norges Bank purchased a new position in CVS Health during the 4th quarter worth $1,092,040,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS traded up $0.70 during trading hours on Friday, reaching $59.06. 14,342,344 shares of the company’s stock traded hands, compared to its average volume of 12,103,906. The firm’s 50 day simple moving average is $60.00 and its 200-day simple moving average is $70.38. The stock has a market cap of $74.14 billion, a PE ratio of 10.26, a price-to-earnings-growth ratio of 0.58 and a beta of 0.53. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. CVS Health Co. has a 12 month low of $52.77 and a 12 month high of $83.25.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The business had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same quarter in the previous year, the business earned $2.20 earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. Equities analysts expect that CVS Health Co. will post 7.02 EPS for the current year.

Insider Buying and Selling

In other news, Director Edward J. Ludwig purchased 1,000 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was acquired at an average price of $53.88 per share, with a total value of $53,880.00. Following the transaction, the director now directly owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.24% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CVS has been the subject of a number of recent analyst reports. SVB Leerink reaffirmed a “market perform” rating and issued a $60.00 price objective (down from $87.00) on shares of CVS Health in a research report on Wednesday, May 1st. Argus dropped their price target on CVS Health from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Wells Fargo & Company lowered their target price on CVS Health from $76.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 7th. Piper Sandler raised their price objective on shares of CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Baird R W upgraded shares of CVS Health to a “hold” rating in a research note on Thursday, May 30th. Eleven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $75.05.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.